Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 25 peer-reviewed journal articles Updated
Rheumatology

Daily Management and Long-Term Monitoring

At a Glance

Takayasu arteritis can remain active even when you feel well or inflammation tests are normal. Long-term care combines symptoms, blood tests, regular imaging, accurate blood pressure checks, and prevention of heart, kidney, and bone complications.

Living with Takayasu Arteritis requires shifting from a “crisis mindset” to one of careful, long-term surveillance. Because this condition can silently progress even when you feel well, successful management depends on a multimodal approach—using multiple different “viewpoints” to ensure the disease is truly quiet [1][2].

Understanding “Normal” Blood Work

In many conditions, a simple blood test for inflammation—like Erythrocyte Sedimentation Rate (ESR) or C-Reactive Protein (CRP)—tells the whole story. In Takayasu Arteritis, these markers are helpful but imperfect [3].

  • The Mismatch: Up to one-third of patients with active vessel inflammation confirmed by imaging or surgery have completely normal ESR and CRP levels [4][5]. Conversely, these markers can rise due to an ordinary infection rather than a vasculitis flare.
  • The Tocilizumab Effect: If you are taking a biologic like tocilizumab, your body’s ability to produce CRP is almost entirely blocked. While this is a sign the drug is working, it means your CRP will look “perfect” even if your arteries are still actively inflamed [3][6].

Because of this, your doctor cannot rely on blood work alone to manage your care. “Normal labs” do not necessarily equal “vascular remission” [3]. However, these trends can still provide useful information when integrated with your symptoms and scans.

Using Scoring Systems for Clarity

To move beyond guesswork, rheumatologists use structured scoring tools to track your disease activity over time.

  • ITAS2010 (Indian Takayasu Clinical Activity Score): This is a checklist of new or worsening symptoms and physical findings [7]. It helps your doctor distinguish between “active disease” (new inflammation) and “damage” (old scarring from previous flares) [8].
  • NIH Criteria: A traditional system that looks for a combination of four factors: new systemic symptoms, new vascular signs (like bruits), elevated lab markers, and new imaging findings [9].

A high score on these scales usually suggests a flare, but a low score isn’t a guarantee of silence. In some studies, patients whose disease was rated “inactive” by these scores still showed new damage on their follow-up scans [7]. These tools help structure the assessment, but they have limited sensitivity. Distinguishing between new active inflammation and old structural damage requires a composite clinical, laboratory, and imaging assessment.

Multimodal Monitoring: The Role of Imaging

Since your symptoms and blood work can’t tell the whole story, serial imaging is a critical component of care.

  • Structural Monitoring: Most experts recommend regular imaging—which may be every 6 to 12 months for some, but the schedule is highly individualized based on symptoms, pregnancy, and kidney function—using MRA or CTA to see if your artery walls are thickening or if new narrowings are forming [10][11].
  • Metabolic Monitoring: PET-CT scans can be used to identify metabolic activity that may represent inflammation, but FDG uptake is not perfectly specific and repeated PET-CT involves radiation exposure [12][4].

Daily Management: Blood Pressure Monitoring

One of the most concrete tasks in your daily life is monitoring your blood pressure. Because Takayasu Arteritis often narrows the arteries leading to the arms, a standard blood pressure reading in one arm may be falsely low [13][14].

  • The Four-Limb Check: Your treating team should perform a baseline assessment of your blood pressure in all four limbs using appropriate equipment and technique. Leg pressures require different cuffs and interpretation [13].
  • Clinician-Directed Assessment: Because involvement can be bilateral or change over time, your team must document the appropriate limb, cuff, and frequency for your home monitoring [15][16].
  • Safe Routine: Never attempt to guess your blood pressure or change your blood pressure medications based on a home reading without direct advice from your clinician [17].

Long-Term Health and Heart Protection

Because Takayasu Arteritis involves your largest arteries, it increases your long-term risk for cardiovascular issues like heart disease or stroke [18][19]. Managing this condition isn’t just about stopping inflammation; it’s about “aggressive prevention”:

  • Cholesterol Management: Keeping your LDL (bad cholesterol) low is vital to prevent atherosclerosis from adding to the narrowing already caused by your vasculitis [20][21].
  • Renal Health: If your renal (kidney) arteries are involved, managing your blood pressure is critical to prevent kidney damage [22][23].
  • Bone Health: If you are on long-term steroids, your team must monitor your bone density and may recommend calcium, vitamin D, or other bone-protective medications [24][25].

Reproductive health and lifestyle factors—like safe vaccinations, appropriate physical activity, and preconception planning—are also vital components of your holistic, long-term care.

Common questions in this guide

Can Takayasu arteritis still be active if my ESR and CRP are normal?
Yes. Normal ESR and CRP do not rule out active artery inflammation, and as many as one in three people with active disease may have normal results. Your clinician must interpret blood tests with symptoms, examination findings, and imaging.
Does tocilizumab make CRP unreliable for Takayasu arteritis monitoring?
Yes. Tocilizumab largely blocks the body's production of CRP, so the result may look normal even when inflammation remains in the arteries. Your care team will use your symptoms and imaging as well as laboratory trends.
How often should I have imaging for Takayasu arteritis?
Imaging schedules are individualized, but some people are monitored with magnetic resonance angiography or CT angiography about every 6 to 12 months. Timing depends on symptoms and factors such as pregnancy and kidney function. PET-CT may be considered in some situations, but its signal is not specific and repeated scans involve radiation.
What should I know about checking my blood pressure at home with Takayasu arteritis?
Artery narrowing can make a reading from one arm falsely low. Your treating team should identify the correct limb, cuff, equipment, and schedule after checking pressures in all four limbs. Do not change blood pressure medicine or interpret an unexpected reading without contacting your clinician.
What do ITAS2010 and NIH criteria show about disease activity?
They are structured tools that combine new symptoms, physical findings, blood tests, and imaging to help distinguish active inflammation from old artery damage. A high score can support concern for a flare, but a low score does not guarantee that disease is quiet. Your clinician should interpret the score as part of a broader assessment.
How can I protect my long-term health with Takayasu arteritis?
Long-term care includes keeping LDL cholesterol controlled, monitoring kidney and blood pressure health, and checking bone density if you use steroids. Your team may also discuss bone-protective treatment, vaccinations, physical activity, and planning for pregnancy. These goals should be individualized to your artery involvement and medicines.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Which specific limb and cuff size should I use for my home blood pressure monitoring, and how frequently should I check it?
  2. 2.At what blood pressure reading (high or low) should I contact the clinic, and what actions should I take?
  3. 3.Based on my current ITAS2010 assessment and imaging, do you consider my disease clinically active?
  4. 4.What is our individualized plan for my follow-up imaging—which modality will we use and roughly when?
  5. 5.What are my specific targets for cholesterol and lifestyle modifications to reduce my long-term cardiovascular risk?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (25)
  1. 1

    Management of Takayasu arteritis.

    Misra DP, Singh K, Rathore U, et al.

    Best practice & research. Clinical rheumatology 2023; (37(1)):101826 doi:10.1016/j.berh.2023.101826.

    PMID: 37246052
  2. 2

    Update in imaging for large vessel vasculitis.

    Nielsen BD, Seitz L, Schmidt WA

    Best practice & research. Clinical rheumatology 2025; (39(3)):102060 doi:10.1016/j.berh.2025.102060.

    PMID: 40180819
  3. 3

    Assessment of inflammatory activity in Takayasu's arteritis: performance of clinical scores and common biomarkers versus 18F-FDG PET/CT.

    Jiménez D, Soto ME, Martínez-Martínez LA, et al.

    Clinical and experimental rheumatology 2021; (39(5)):1011-1020 doi:10.55563/clinexprheumatol/a71bzh.

    PMID: 33124558
  4. 4

    Outcome Measures and Biomarkers for Disease Assessment in Takayasu Arteritis.

    Misra DP, Jain N, Ora M, et al.

    Diagnostics (Basel, Switzerland) 2022; (12(10)) doi:10.3390/diagnostics12102565.

    PMID: 36292253
  5. 5

    Treatment of Takayasu arteritis with the IL-6R antibody tocilizumab vs. cyclophosphamide.

    Kong X, Zhang X, Lv P, et al.

    International journal of cardiology 2018; (266()):222-228 doi:10.1016/j.ijcard.2017.12.066.

    PMID: 29729868
  6. 6

    Perioperative Management of Takayasu Arteritis for Cardiac Surgery　- Review and Single-Center Experience.

    Arita Y, Asano R, Ueda J, et al.

    Circulation journal : official journal of the Japanese Circulation Society 2025; (89(12)):1849-1856 doi:10.1253/circj.CJ-24-0496.

    PMID: 39523007
  7. 7

    Assessment of Patients with Takayasu Arteritis in Routine Practice with Indian Takayasu Clinical Activity Score.

    Alibaz-Oner F, Aydin SZ, Akar S, et al.

    The Journal of rheumatology 2015; (42(8)):1443-7 doi:10.3899/jrheum.140817.

    PMID: 26136490
  8. 8

    Derivation and Validation of a New Disease Activity Assessment Tool With Higher Accuracy for Takayasu Arteritis.

    Kwon OC, Park MC

    Frontiers in immunology 2022; (13()):925341 doi:10.3389/fimmu.2022.925341.

    PMID: 35784279
  9. 9

    Efficacy of Tofacitinib in Takayasu Arteritis Refractory to Biologic DMARDs-A Multicentre Study in Indian Patients.

    Vasanth P, Aithala R, Ganapati A, et al.

    International journal of rheumatic diseases 2025; (28(6)):e70293 doi:10.1111/1756-185X.70293.

    PMID: 40432338
  10. 10

    Analysis of predictive factors for treatment resistance and disease relapse in Takayasu's arteritis.

    Sun Y, Ma L, Chen H, et al.

    Clinical rheumatology 2018; (37(10)):2789-2795 doi:10.1007/s10067-018-4094-2.

    PMID: 29687289
  11. 11

    Association of PET vascular activity score with Takayasu's arteritis angiographic progression.

    Wu S, Wu B, Ma L, et al.

    European journal of nuclear medicine and molecular imaging 2025; (52(11)):4268-4280 doi:10.1007/s00259-025-07348-2.

    PMID: 40434493
  12. 12

    Imaging for Diagnosis, Monitoring, and Outcome Prediction of Large Vessel Vasculitides.

    Schäfer VS, Jin L, Schmidt WA

    Current rheumatology reports 2020; (22(11)):76 doi:10.1007/s11926-020-00955-y.

    PMID: 32959107
  13. 13

    Clinical course and prognostic factors of childhood Takayasu's arteritis: over 15-year comprehensive analysis of 101 patients.

    Fan L, Zhang H, Cai J, et al.

    Arthritis research & therapy 2019; (21(1)):31 doi:10.1186/s13075-018-1790-x.

    PMID: 30670069
  14. 14

    2022 American College of Rheumatology/EULAR Classification Criteria for Takayasu Arteritis.

    Grayson PC, Ponte C, Suppiah R, et al.

    Arthritis & rheumatology (Hoboken, N.J.) 2022; (74(12)):1872-1880 doi:10.1002/art.42324.

    PMID: 36349501
  15. 15

    Takayasu Arteritis Presenting as Renovascular Hypertension and Renal Failure in a Patient with Factor VII Deficiency.

    Ozkok S, Aslan A, Gulseren Y, et al.

    The Eurasian journal of medicine 2018; (50(3)):210-212 doi:10.5152/eurasianjmed.2018.17324.

    PMID: 30515046
  16. 16

    Takayasu arteritis, an atypical presentation as chronic kidney disease.

    Neeraja V, Nakka V, Mahadev M, et al.

    African health sciences 2023; (23(1)):781-784 doi:10.4314/ahs.v23i1.82.

    PMID: 37545973
  17. 17

    Anaesthetic Management of Patients with Takayasu's Arteritis for Open Cholecystectomy.

    Shrestha GS, Shrestha N, Shrestha BK, Shrestha PS

    JNMA; journal of the Nepal Medical Association 2015; (53(198)):144-7.

    PMID: 26994039
  18. 18

    Cardiovascular and Renal Morbidity in Takayasu Arteritis: A Population-Based Retrospective Cohort Study From the United Kingdom.

    Goel R, Chandan JS, Thayakaran R, et al.

    Arthritis & rheumatology (Hoboken, N.J.) 2021; (73(3)):504-511 doi:10.1002/art.41529.

    PMID: 32969145
  19. 19

    Cardiovascular Disease in Large Vessel Vasculitis: Risks, Controversies, and Management Strategies.

    Clifford AH

    Rheumatic diseases clinics of North America 2023; (49(1)):81-96 doi:10.1016/j.rdc.2022.08.004.

    PMID: 36424028
  20. 20

    Factors associated with event-free survival in Chinese patients with Takayasu's arteritis.

    Wei Y, Zhao C, Liang J, et al.

    Clinical rheumatology 2021; (40(5)):1941-1948 doi:10.1007/s10067-020-05481-x.

    PMID: 33140238
  21. 21

    Impact of non-immunosuppressive medical therapy on disease progression and complications of Takayasu arteritis: A narrative review.

    Terribili R, Conticini E, Grazzini S, et al.

    Autoimmunity reviews 2024; (23(12)):103656 doi:10.1016/j.autrev.2024.103656.

    PMID: 39374636
  22. 22

    Demographic, Clinical, and Radiologic Characteristics of a Cohort of Patients with Takayasu Arteritis.

    Sanchez-Alvarez C, Mertz LE, Thomas CS, et al.

    The American journal of medicine 2019; (132(5)):647-651 doi:10.1016/j.amjmed.2018.12.017.

    PMID: 30615861
  23. 23

    Risk of rupture of an aortorenal vein graft aneurysm after the surgical repair of Takayasu arteritis-induced right renal artery stenosis: A case report and a literature review.

    Chen X, Huang B, Yuan D, et al.

    Medicine 2019; (98(48)):e17889 doi:10.1097/MD.0000000000017889.

    PMID: 31770201
  24. 24

    Standard and biological treatment in large vessel vasculitis: guidelines and current approaches.

    Muratore F, Pipitone N, Salvarani C

    Expert review of clinical immunology 2017; (13(4)):345-360 doi:10.1080/1744666X.2017.1285699.

    PMID: 28116918
  25. 25

    Ocular Manifestations in an Italian Cohort of Patients with Takayasu Arteritis.

    Dammacco R, Cimino L, De Simone L, et al.

    Ocular immunology and inflammation 2023; (31(5)):945-954 doi:10.1080/09273948.2022.2072348.

    PMID: 35584335

This page explains daily monitoring and long-term care for Takayasu arteritis for informational purposes only and does not constitute medical advice. Your rheumatology team should set your blood pressure, imaging, medication, and lifestyle plan.

Get notified when new evidence is published on Takayasu arteritis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.